Trials / Completed
CompletedNCT06039449
A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2
A Study to Evaluate the Efficacy and Safety of VYD222 for Prevention of COVID-19 (CANOPY)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 790 (actual)
- Sponsor
- Invivyd, Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or older who are at risk of exposure to SARS-CoV-2
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VYD222 (pemivibart) | Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with VYD222. |
| DRUG | Normal saline | Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with Placebo. |
Timeline
- Start date
- 2023-09-08
- Primary completion
- 2024-11-19
- Completion
- 2024-11-19
- First posted
- 2023-09-15
- Last updated
- 2024-12-09
Locations
18 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06039449. Inclusion in this directory is not an endorsement.